‘Pomalyst’ Is Proposed Brand Name For Pomalidomide
Celgene has proposed ‘Pomalyst’ as the trademarked brand name for pomalidomide.
The name was made public this morning in a press release by Celgene (NASDAQ: CELG), the company developing pomalidomide. The press release contains information about the company's expected financial results for 2012 and forecasts for 2013 and later years.
In the press release, Celgene refers to pomalidomide primarily by its new proposed brand name, Pomalyst. This is the first time the company has used the proposed brand name in a public document or presentation.
Pomalidomide belongs to the same class of drugs as thalidomide (Thalomid) and Revlimid (lenalidomide) – two drugs that Celgene already markets as myeloma treatments in the United States and internationally. Celgene is developing pomalidomide as a potential new treatment for multiple myeloma and for myelofibrosis, a disorder of the bone marrow in which the marrow is replaced by scar (fibrous) tissue.
|
MORE INFORMATION: News articles about: Forum discussions about: - Pomalyst |
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are both currently reviewing applications for the approval of pomalidomide in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma patients who have received at least two prior therapies.
The FDA is required to make its decision about pomalidomide’s new drug application by February 10, 2013.
Pharmaceutical companies such as Celgene discuss a new drug’s proposed brand name with the FDA during the agency’s review of a drug. Brand names are not typically finalized, however, until close to the time a drug is approved by the FDA and is ready to be launched for general use.
Celgene's announcement of Pomalyst as the brand name for pomalidomide can therefore be interpreted as a sign the company is anticipating FDA approval of pomalidomide sometime in the near future.
There was a time when Celgene was considering using the brand name "Actimid" for pomalidomide. Many older press releases and other documents from the company make use of that brand name.
However, the company stopped using Actimid as a potential brand name for the drug several years ago, and it has been mum about the final brand name for pomalidomide until today's press release.
For more information, please see the Celgene press release.
Related Articles:
- ASCO 2018 Update – Expert Perspectives On The Key Multiple Myeloma-Related Oral Presentations
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
- Once-Weekly High-Dose Kyprolis Yields Deeper Responses And Longer Remissions Than Twice-Weekly Kyprolis (ASCO & EHA 2018)
- ECT-001 Granted Regenerative Medicine Advanced Therapy (RMAT) Designation By U.S. FDA
Pomalyst sounds fine, and is easy to pronounce. I certainly expect swift FDA approval soon. Then Kyprolis and Pomalyst (eventually maybe with elotuzumab) will be the combination of choice for heavily pretreated MM patients.
But the real breakthrough awaits an immunologic approach, which will help our own T cells (or B on NK cells) reliably and selectively target the rogue malignant plasma cells which are our scourge. May it be so in our lifetimes! Jan
I think that 'Pomalyst' is a very good name for the new drug, a.k.a. Actimid or Pomalidomide. Somehow 'Actimid' is quite generalized, whereas 'Pomalidomide' reminds me of apples...'les pommes' in French! The name 'Pomalyst' reminds one of a 'catalyst', an agent of chemical change. Hope that it helps out a lot of patients...it seems that getting a new drug for myeloma always does that.
Get new Myeloma Beacon articles by email.